Personalized brain stimulation for treating amphetamine addiction
Individualized Neuromodulation Intervention Techniques for the Core Clinical Features of Drug Addiction
This study tests a personalized brain stimulation method to see if it can help people addicted to methamphetamine by reducing their cravings more effectively than standard treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Shanghai Mental Health Center Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT06165198 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of closed-loop transcranial alternating current stimulation (tACS) tailored to specific EEG biomarkers in individuals dependent on methamphetamine. By analyzing brain activity related to cravings, the researchers aim to deliver targeted stimulation to the prefrontal cortex and other regions to reduce cravings and improve treatment outcomes. The study compares the effectiveness of this individualized approach against traditional open-loop tACS methods, focusing on the neurological and behavioral effects of the intervention.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 18 to 45 with a history of amphetamine use for at least one year and who meet DSM-V criteria for addiction severity.
Not a fit: Patients with severe cognitive impairments, other substance dependencies, or severe mental illnesses may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce cravings and improve treatment outcomes for individuals struggling with amphetamine addiction.
How similar studies have performed: While the approach of using neuromodulation for addiction treatment is gaining traction, this specific individualized method using closed-loop tACS is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals aged between 18 and 45 years, irrespective of gender, having completed a minimum of 9 years of education and capable of effectively cooperating in questionnaire evaluations. * Meet the diagnostic criteria set forth by the DSM-V concerning the severity of amphetamine-type substance addiction. * A history of utilizing amphetamine-type substances for a duration not less than one year, with a frequency of use being at least once per week. * Consent to actively cooperate in the completion of subsequent follow-up assessments. Exclusion Criteria: * Severe cognitive functional impairments manifested through a history of head trauma, cerebrovascular diseases, epilepsy, etc., or usage of cognitive enhancement drugs in the past 6 months; an intellectual disability with an IQ score less than 70. * A diagnosis of schizophrenia or other severe mental illnesses as per the DSM-5 criteria. * Abuse or dependence on other psychoactive substances (excluding nicotine) within the past 5 years. * Severe organic diseases that might compromise study participation. * Contraindications to tACS, such as a history of epileptic seizures or the presence of metallic implants in proximity to the head.
Where this trial is running
Shanghai, Shanghai
- Shanghai Mental Health Center — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Min Zhao, PhD
- Email: drminzhao@gmail.com
- Phone: 64387250
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.